Breast Cancer Research Review Issue 80
Palbociclib for hormone-receptor+, HER2+ advanced breast cancer
Sacituzumab govitecan + pembrolizumab for advanced TNBC
TDP for HER2+ metastatic breast cancer
PROs for SERENA-6: camizestrant + CDK4/6 inhibitor in advanced ESR1-mutated breast cancer
Camizestrant + capivasertib for oestrogen receptor+, HER2– advanced breast cancer
Chemotherapy in lymph node-negative invasive papillary breast cancer
Extended endocrine therapy after adjuvant LHRH in premenopausal node+, hormone receptor+ breast cancer
Adding ipatasertib to dual anti-HER2 maintenance in PIK3CA-mutated HER2+ metastatic breast cancer
Sapacitabine + olaparib in BRCA1/2-mutated metastatic breast cancer
Neoadjuvant trastuzumab deruxtecan alone or followed by THP for high-risk HER2+ early breast cancer
Expert contributor
Dr Hilary Martin
Dr Hilary Martin, is a medical oncologist at Fiona Stanley Hospital Perth subspecialising in breast cancer. Her initial oncology training was undertaken in South Australia. She subsequently worked as a breast unit fellow at the Royal Marsden Hospital, London, and also as a clinical fellow at Royal Perth Hospital. She has a Masters of Public […]
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.